一个新的火柴大小的植入物可以“革命性”发现改变了艾滋病患者治疗的方式，专家称。此装置，这是类似于避孕植入设计坐在皮肤下面，提供抗逆转录病毒药物的患者。

　　研究表明，严格遵守这些药物是重要的抑制HIV。原理主要是由工作是通过抑制病毒的复制，在体内，使免疫系统自我修复，并有助于防止任何进一步的损害。他们减少HIV病毒数量在患者的血液中病毒量至很低，或检测不到的水平。与病毒，HIV是不能够破坏人的免疫系统。这种形式的治疗，也可作为预防HIV传播的手段。

　　那些成功的艾滋病治疗计划不太可能把病毒传给性伴侣，同样一个母亲是不可能把它传给一个未出生的孩子。但患者能坚持斗争的药方，通常在一些不同的药物。通过联合治疗，因为它是已知的，通常涉及一个病人服用三抗逆转录病毒药物，因为艾滋病病毒可以迅速适应，并成为抗药。但是在加利福尼亚科学研究所的科学家们相信他们的橡树顶的新发明可以提供一个更有效的治疗手段。

　　该装置的工作原理是在一段时间内持续提供一定量的抗逆转录病毒药物。在动物的早期试验显示无副作用在一段40天。橡树脊研究作者和创始人，Marc鲍姆，说：“据我们所知，这是第一个植入物被用于这一目的。“这种新的设备将彻底改变我们如何治疗或预防HIV和艾滋病，它提供了强大的HIV戒毒，消除了一个在艾滋病预防坚持正确的给药方案的关键障碍。”

　　医生和科学家们承认，当前治疗的主要缺点是患者坚持服用药物的问题。“这是不幸的，但患者并不总是遵循剂量说明书规定，”他说。在临床试验中不稳定的药物有LED高度可变的疗效。“这是我们的最高使用的艾滋病预防皮下埋植剂的可能的利益。”

　　植入物，一个小的柔性管，措施约40mm长，是用来插入皮肤下的医疗保健专业。鲍姆博士说：“我们的皮下埋植剂是用以同样的方式作为避孕植入物。“这是很容易插入和删除并提供持续的强有力的促药物替诺福韦alafenamide释放。这是大约10倍的强效抗HIV病毒比替诺福韦酯-另一个亲的药物已被证明是预防艾滋病性传播，当作为暴露前预防。“我们正在与我们的初步研究结果非常满意，并正在努力开发一种预防艾滋病，将满12个月仍有效的皮下埋植剂。”

　　鲍姆博士的团队的研究结果发表在杂志抗菌药物和化疗。

　　原文

　　HIV implant could 'revolutionise' the way patients are treated, by releasing drugs automatically into the body

　　A new matchstick-sized implant could 'revolutionise' the way HIV patients are treated, experts claim.The device, which is similar to the contraceptive implant and is designed to sit underneath the skin, delivers antiretroviral drugs to patients.

　　Research has shown strict adherence to these medicines is vital in suppressing HIV.They work by preventing the virus from replicating in the body, allowing the immune system to repair itself, and help prevent any further damage.They reduce the amount of HIV in a sufferer's blood - their viral load - to very low, or undetectable levels.With an undetectable viral load, HIV is not able to damage a person's immune system.This form of treatment can also be used as a means of preventing the spread of HIV.

　　Those on successful HIV treatment plans are unlikely to pass on the virus to a sexual partner, and similarly a mother is less likely to pass it to an unborn child.But patients can struggle to adhere to their prescriptions, typically juggling a number of different drugs to take.

　　Combination therapy, as it is known, usually involves a patient taking three antiretrovirals, because HIV can adapt quickly, and become resistant to drugs.'It's unfortunate, but patients do not always follow the dosing instructions as prescribed,' he said.'In clinical trials erratic administration of drugs has led to highly variable efficacy outcomes.'That's what peaked our interest in the possible use of a subdermal implant for the prevention of HIV.'

　　The implant, a small flexible tube, measures around 40mm in length and is designed to be inserted under the skin by a healthcare professional.Dr Baum added: 'Our subdermal implant is used in the same manner as a contraceptive implant.

　　'It is easily inserted and removed and provides sustained release of the potent pro-drug tenofovir alafenamide.'This is roughly 10 times more potent against HIV than tenofovir disoproxil fumarate - another pro-drug that has been shown to prevent sexually transmitted HIV, when used as a pre-exposure prophlaxis.'We are very pleased with the results of our preliminary studies and are working diligently to develop a subdermal implant for HIV prevention that will remain effective for a full 12 months.'

　　Dr Baum's teams' findings were published in the journal Antimicrobial Agents and Chemotherapy.